



IFW

Atty. Dkt. No. 342837-1553
Application Serial No. 10/748,089

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrei W. KONRADI et al.

Title: HETEROARYL,
HETEROCYCLIC AND ARYL
COMPOUNDS WHICH INHIBIT
LEUKOCYTE ADHESION
MEDIATED BY VLA-4

Appl. No.: 10/748,089

Filing Date: 12/29/2003

Examiner: Not yet assigned

Art Unit: 1614

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
_____ Esther Lily C. Esguerra (Printed Name)	
_____  (Signature)	
_____ January 13, 2005 (Date of Deposit)	

SECOND REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attn: Application Processing Division, Customer Correction Branch

Sir:

Attached is a copy of the official Filing Receipt received from the PTO in the above-referenced application. The filing receipt comprises errors with respect to the Domestic Priority Data.

Applicants previous Request for Corrected Filing Receipt, filed on May 26, 2004, inadvertently failed to identify U.S. Patent Application Serial No. 09/489,377, which preserved continuity between the previously identified provisional applications and the instant application.

Atty. Dkt. No. 342837-1553
Application Serial No. 10/748,089


Applicants herewith provide the following priority data for the instant application:

This application is a Continuation of U.S. Application 10/251,442, filed 9/20/2002, which is a Divisional of U.S. Patent Application 09/489,377, filed 1/21/2000, which claims the benefit of U.S. Provisional Application No. 60/116,923, filed 1/22/1999 and U.S. Provisional Application No. 60/160,999, filed 10/21/1999; the enclosures of which are incorporate herein by reference in their entirety.

Applicants believe that no fee is due because Application 09/489,377 was properly identified in the executed Declarations; however, the Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872.

Respectfully submitted,

Date: January 13, 2005

By 

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 856-3755
Facsimile: (650) 856-3710

Stephen Todd, Ph.D.
Attorney for Applicant
Registration No. 47,139



UNITED STATES PATENT AND TRADEMARK OFFICE

APR 20 2004

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/748,089	12/29/2003	1614	770	42837-20010.21		1	1

SWISS LAW GROUP
 Building 3, Ste. 100
 Palo Alto Square
 3000 El Camino Real
 Palo Alto, CA 94306



CONFIRMATION NO. 6848
FILING RECEIPT



OC000000012340035

Date Mailed: 04/14/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Andrei W. Konradi, San Francisco, CA;
 Michael A. Pleiss, Sunnyvale, CA;
 Eugene D. Thorsett, Half Moon Bay, CA;
 Susan Ashwell, Plainsboro, NJ;
 Gregory S. Welmaker, Jackson, NJ;
 Anthony Kreft, Langhorne, PA;
 Dimitrios Sarantakis, Newtown, PA;
 Darren B. Dressen, San Mateo, CA;
 Francine S. Grant, Milpitas, CA;
 Christopher Semko, Fremont, CA;
 Ying-Zi Xu, Fremont, CA;

Assignment For Published Patent Application

Elan Pharmaceuticals, Inc.;
 American Home Products Corporation.;

Domestic Priority data as claimed by applicant

This application is a CON of 10/251,442 09/20/2002

which is a Divisional of U.S. Patent Application 09/489,377, filed 1/21/2000,
 which claims the benefit of U.S. Provisional Application No. 60/116,923, filed
 1/22/1999 and U.S. Provisional Application No. 60/160,999, filed 10/21/1999

If Required, Foreign Filing License Granted: 04/12/2004

Projected Publication Date: 07/22/2004

Non-Publication Request: No

Early Publication Request: No

Title

Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).